Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

1.870 +0.080 (+4.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ALX Oncology Holdings Inc. - Common Stock

< Previous 1 2 3 Next >
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Participate in Upcoming Investor Conferences in September
From ALX Oncology
Via GlobeNewswire
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
From ALX Oncology
Via GlobeNewswire
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host Virtual R&D Day on March 5, 2025
Company leadership and external key opinion leaders to highlight clinical program progress and provide business and financial updates 
From ALX Oncology
Via GlobeNewswire
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development 
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces November Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual... 
From ALX Oncology
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.